Shows
GRACEcast - Discussions with the Global Resource for Advancing Cancer EducationPreferential Timing for Molecular Testing in NSCLCDr. Tejas Patil discusses when to utilize molecular testing in patients with NSCLC. For full video visit cancerGRACE.org.2022-09-2103 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationMelanoma Updates - Molecular Profiling and Driver Mutations in Melanoma TreatmentMeredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma. Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.A huge thank you to our sponsors #Merck and #Exelixis!For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.2022-02-0408 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationMelanoma Updates - The Importance of Screening for Skin CancersDr. Meredith McKean discusses the importance of skin cancer screenings. Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma. Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.A huge thank you to our sponsors #Merck and #Exelixis!For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.2022-02-0103 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationMelanoma Updates -- Leptomeningeal Disease/ Brain Mets in MelanomaMeredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma. Dr. Roman Groisberg discusses Leptomeningeal disease and brain metastases in melanoma patients.A huge thank you to our sponsors #Merck and #Exelixis!For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.2022-02-0105 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationMelanoma Updates The Role of Neoadjuvant Treatment in Melanoma CareDr. Meredith McKean discusses neoadjuvant treatment for melanoma patients.Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma. Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.A huge thank you to our sponsors #Merck and #Exelixis!For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.2022-01-2406 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationMelanoma Updates Treatment Options for Metastatic MelanomaDr. Douglas Johnson discusses treatment options for patients with metastatic melanoma.Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma. A huge thank you to our sponsors #Merck and #Exelixis!For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.2022-01-2407 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationMelanoma Updates Potential Toxicities Associated with Immunotherapy in the Treatment of MelanomaDr. Douglas Johnson discusses the potential toxicities that are associated with immunotherapy in melanoma patients.Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma. A huge thank you to our sponsors #Merck and #Exelixis!For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.2022-01-2406 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationMelanoma Updates - Adjuvant Treatment Options for MelanomaMeredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma. Dr. Roman Groisberg discusses options for adjuvant treatment in patients with melanoma.A huge thank you to our sponsors #Merck and #Exelixis!For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.2022-01-2110 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationGRACEcast - Leading Treatment Options for Patients with Negative Tumor PD-L1 NSCLC with Dr. Stephen LiuDr. Stephen Liu, member of the GRACE faculty, discusses leading treatment options for patients with negative tumor pdl-1 in non small cell lung cancer. For more information visit www.cancerGRACE.org2020-10-2806 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationGRACEcast - Immunotherapy for Small Cell Lung Cancer with Dr. Stephen LiuDr. Stephen Liu, member of the GRACE faculty, discusses immunotherapy for small cell lung cancer. For more information visit www.cancerGRACE.org2020-10-2108 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationGRACEcast - Emerging Molecular Targets in NSCLC- RET Fusions with Dr. Josh BaumlDr. Josh Bauml, member of the GRACE faculty, discusses emerging molecular targets in non small cell lung cancer for RET fusions.For more information visit www.cancerGRACE.org2020-10-1406 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationGRACEcast - Emerging Molecular Targets in NSCLC- MET with Dr. Josh BaumlDr. Josh Bauml, member of the GRACE faculty, discusses emerging molecular targets in non small cell lung cancer with a MET mutation. for more information visit www.cancerGRACE.org2020-10-0707 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationGRACEcast 2020 - Updates in Small Cell Lung Cancer with Dr. Jared WeissDr. Jared Weiss, GRACE VP on the Board of Directors and Faculty for GRACE discusses updates for the treatment of Small Cell Lung Cancer.For more info, visit www.cancerGRACE.org2020-09-3007 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion - EGFR Mutation Patient Progression and Next StepsFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds patient progression in a case with EGFR mutation, and what are the next steps. 2020-09-0909 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion - EGFR Mutation and High PDL1 - What is the Role of Immunotherapy in Treatment DecisionsFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds a case with an EGFR Mutation and High PDL1. The discussion centers around the role...2020-09-0205 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion - EGFR Mutation with MET Amplification Treatment Decisions and the Importance of the Level of MET AmplificationFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation with MET amplification. They review treatment decisions and the importance of the...2020-08-2606 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationWebside Discussions Update - Pt 3 - Challenges and the Future for In Person Patient CareIn part three of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy discuss cancer and Covid-19 and how the ongoing pandemic is effecting in person patient care.Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient CarePart 2 - Update on the Use of Telemedicine in Patient Care During the PandemicPart 3 - Challenges and the Future Outlook for In Person...2020-08-1912 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationWebside Discussions Update Pt 2 - Update on the Use of Telemedicine in Patient Care During the PandemicIn part two of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss an update on the use of telemedicine in patient care during the pandemic.Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient CarePart 2 - Update on...2020-08-1216 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationWebside Discussion Update Part 1- How Has the Coronavirus Pandemic Changed Cancer Management in Patient CareIn part one of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss changes to management in patient care, the use of telemedicine and future challenges, as well as other issues relating to a cancer diagnosis in the middle of a pandemic.Part 1...2020-08-0516 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion - What is the Recommended Treatment for Common EGFR MutationsFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this discussion they review the recommended treatment for a common EGFR mutation. For more, please visit http://cancerGRACE...2020-07-2906 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion - EGFR Mutation Treated with Tagrisso Progression While on Treatment, and What is the Role of Repeat BiopsyFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation treated with Tagrisso, and progression while on treatment. The doctors also...2020-07-2204 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationWebside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 3In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create...2020-07-1514 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationWebside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 2In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create...2020-07-0809 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationWebside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 1In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike. Does this new process create...2020-07-0112 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion - EGFR Mutation Oligoprogression in Brain and or Body vs Worsening Progression What are the Treatment Options?For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?For more...2020-06-2405 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion 3.1 EGFR Mutation - Chemotherapy and an EGFR Inhibitor Concurrently or Sequentially in Treatment Decisions?For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?For more...2020-06-2408 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion 2019 3. EGFR Uncommon Exon 20 Mutation - Suggested Treatments Targeted Therapy and Clinica TrialFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to an EGFR mutation. In this podcast, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials. For...2020-04-2206 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCorona Virus and Covid 19 - Key Questions Part Four - Is the Standard Care Changing for Cancer Patients Because of the Pandemic?In this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. ...2020-04-1912 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCorona Virus and Covid 19 - Key Questions Part Three - What Preventive Measures are Trustworthy?In this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. ...2020-04-1805 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCorona Virus and Covid 19 - Key Questions Part Two - Do Cancer Patients Have a Higher Risk?In this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. ...2020-04-1706 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCorona Virus and Covid 19 - Key Questions Part One - Should Cancer Patients Get Tested?In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients. In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic. ...2020-04-1708 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationCase Based Panel Discussion 2019 3.2 EGFR Mutation and the FLAURA Trial, Is There a Difference in Data Based on DemographicsFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect...2020-04-1508 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationUnresectable NSCLC - Does Checkmate 227's Suggestion of an Immunotherapy Combination of Yervoy and Opdivio Offer Another Treatment Option?Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma...2020-04-0810 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationUnresectable NSCLC - Tumor Mutational Burden (TMB), the Value in TestingDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma...2020-04-0106 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationUnresctable NSCLC - Concurrent Chemo & Radiation, Followed By Immunotherapy, Potential Pneumonitis Following Durvalumab (Imfinzi)Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and...2020-03-2505 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationUnresectable NSCLC - For Varying Patient Scenarios, Fragile Patient, Attrition after 8-9 Months, What is the Best Schedule for DurvalumabDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma...2020-03-1809 minGRACEcast - Discussions with the Global Resource for Advancing Cancer EducationUnresectable NSCLC - Treatment Standard Concurrent Chemo & Rad Followed by Immunotherapy, Approach for Patients with PDL1 Score of 0Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma...2020-03-1107 min
GRACEcast Lung Cancer AudioSquamous Lung Cancer Part 5, Q and A Session (audio)Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.2013-12-2013 min
GRACEcast Lung Cancer AudioSquamous Lung Cancer, Part 4: Immunotherapy (audio)Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.2013-12-1107 min
GRACEcast Lung Cancer AudioSquamous Lung Cancer, Part 3: Treatment (audio)Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.2013-12-0912 min
GRACEcast Lung Cancer AudioSquamous Lung Cancer, Part 2: Genomic Testing (audio)Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.2013-12-0611 min
GRACEcast Lung Cancer AudioSquamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.2013-12-0315 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.2013-09-0405 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.2013-08-3105 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.2013-08-2705 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.2013-08-2705 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.2013-08-2309 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.2013-08-2307 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.2013-08-1604 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.2013-08-1606 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.2013-08-1612 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.2013-08-1406 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.2013-08-1308 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (audio)Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.2013-08-1108 min
GRACEcast Lung Cancer AudioASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (audio)Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.2013-08-0707 min
GRACEcast Head and Neck Cancer AudioHPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly2013-07-2207 min
GRACEcastHPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly2013-07-2207 minGRACEcast ALL Subjects audio and videoHPV in Head and Neck Cancer, Part 1: What is it and What Does it Mean? (audio)GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly2013-07-2207 min
GRACEcast Lung Cancer AudioDr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.2013-06-0921 min
GRACEcast Lung Cancer AudioDr. Antoinette Wozniak on Small Cell Lung Cancer: Introduction, Diagnosis, and Staging (audio)Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.2013-05-3016 min
GRACEcast Lung Cancer AudioRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 3): Evidence to Support a New, Biology-Based Staging System (audio)Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.2013-05-2119 min
GRACEcast ALL Subjects audio and videoGRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, CanadaDr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.2013-05-1702 minGRACEcast Lung Cancer VideoGRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology, CanadaDr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.2013-05-1702 min
GRACEcastGRACE, cancerGRACE, GRACEcast, advanced NSCLC, Rosalyn Juergens, McMaster University, molecular oncology, targeted therapy, NSCLC histology,Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.2013-05-1702 min
GRACEcast Lung Cancer AudioRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis (audio)Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).2013-05-1711 min
GRACEcast Lung Cancer AudioRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 1): Potential Value of Molecular Staging (audio)Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).2013-05-1312 min
GRACEcast Lung Cancer AudioHighlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.2013-04-0703 min
GRACEcast Lung Cancer AudioHighlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (audio)Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.2013-03-3008 min
GRACEcast Lung Cancer AudioHighlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.2013-03-3005 min
GRACEcast Lung Cancer AudioHighlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.2013-03-2310 min
GRACEcast Lung Cancer AudioHighlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.2013-03-1918 min
GRACEcast Lung Cancer AudioDr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.2013-03-1210 min
GRACEcast Lung Cancer AudioDr. Harpole on Lung Surgery: Advances in Lung Cancer Staging (audio)Dr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.2013-02-1111 min
GRACEcast Radiation Oncology VideoCan we safely combine Tarceva with brain radiation for lung cancer with brain radiation?Dr. Jack West describes a case series that illustrates the safety of giving whole brain radiation along with concurrent Tarceva (erlotinib) for patients with lung cancer and brain metastases.2013-02-0803 min
GRACEcast Radiation Oncology VideoIs there an alternative to brain radiation for patients with several brain metastases?Dr. Jack West reviews a case that illustrates the potential option of systemic therapy for brain metastases before initiating whole brain radiation.2012-12-0505 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 6: Moving Radiation Developments into Metastatic Lung Cancer (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.2012-11-2505 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 6: Moving Radiation Developments into Metastatic Lung Cancer (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews the rationale and feasibility of using focal radiation in the setting of metastatic lung cancer.2012-11-2505 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 5: New Techniques (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes new technologies that are improving the accuracy and safety of radiation for stage non-small cell lung cancer (NSCLC).2012-11-1510 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 5: New Techniques (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes new technologies that are improving the accuracy and safety of radiation for stage non-small cell lung cancer (NSCLC).2012-11-1510 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 4: Defining a Role for SBRT (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, covers the benefits and limitations of stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC).2012-11-0806 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 4: Defining a Role for SBRT (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, covers the benefits and limitations of stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC).2012-11-0806 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 3: Recent Successes and Open Questions (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews recent successful experiences with stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer and reviews several open questions about this strategy.2012-11-0506 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 3: Recent Successes and Open Questions (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, reviews recent successful experiences with stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer and reviews several open questions about this strategy.2012-11-0506 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 2: The Rationale for Stereotactic Body Radiation Therapy, by Dr. Vivek Mehta (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes the ways to modulate the efficacy of radiation and explains why stereotactic body radiation therapy (SBRT) may be particularly effective for early lung cancer.2012-11-0109 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 2: The Rationale for Stereotactic Body Radiation Therapy, by Dr. Vivek Mehta (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, describes the ways to modulate the efficacy of radiation and explains why stereotactic body radiation therapy (SBRT) may be particularly effective for early lung cancer.2012-11-0109 min
GRACEcast Radiation Oncology VideoRefining Radiation Therapy for Lung Cancer, Part 1: A Historical Perspective, by Dr. Vivek Mehta (video)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, provides a historical perspective of radiation therapy as it transitions to a more targeted treatment approach.2012-10-2810 min
GRACEcast Radiation Oncology AudioRefining Radiation Therapy for Lung Cancer, Part 1: A Historical Perspective, by Dr. Vivek Mehta (audio)Dr. Vivek Mehta, Radiation Oncologist at Swedish Cancer Institute in Seattle, WA, provides a historical perspective of radiation therapy as it transitions to a more targeted treatment approach.2012-10-2810 min
GRACEcast Lung Cancer AudioManaging Pulmonary Complications of Lung Cancer Treatment: Targeted Therapy and Radiation-Induced Lung Damage (audio)Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.2012-10-2514 min
GRACEcast Lung Cancer AudioManaging Pulmonary Complications of Lung Cancer Treatment: Chemo-Induced Lung Damage (Audio)Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.2012-10-1517 min
GRACEcast Lung Cancer AudioASCO 2012 Lung Cancer Highlights: Question and Answer Session (audio)Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.2012-09-2920 min
GRACEcast Lung Cancer AudioASCO 2012 LC Highlights: Dr. Joel Neal on Molecular Targets in Squamous NSCLC (audio)Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.2012-09-2104 min
GRACEcast Lung Cancer AudioASCO 2012 LC Highlights: Dr. Joel Neal on the SELECT Trial of Tarceva (Erlotinib) As Adjuvant Therapy for EGFR Mutation-Positive Advanced NSCLC (audio)Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer. 2012-09-1704 min
GRACEcast Lung Cancer AudioASCO 2012 LC Highlights: Dr. Joel Neal on the LUX-Lung 3 Trial of Afatinib vs. Chemo for EGFR Mutation-Positive Advanced NSCLC (audio)Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.2012-09-1205 min
GRACEcast Lung Cancer AudioASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (audio)Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).2012-09-1105 min
GRACEcast Radiation Oncology AudioGRACEcast Feeds Moving (audio)The GRACEcast feeds on iTunes are moving!2012-03-1401 min
GRACEcast Radiation Oncology VideoGRACEcast Feeds Moving (video)The GRACEcast feeds on iTunes are moving!2012-03-1401 min
GRACEcast Radiation Oncology VideoInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (video)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 min
GRACEcast Radiation Oncology AudioInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (audio)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 min
GRACEcast Radiation Oncology VideoVivek Mehta Interview (video)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1423 minGRACEcast Radiation Oncology AudioVivek Mehta Interview (audio)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1423 min